Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 14/20 | 1.00 |
| ▸ | HTR3A | P46098 | 5/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.67 |
| ▸ | HTR3B | O95264 | 3/20 | 0.67 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.67 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844378 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843638 | 0.95 | CHRNA7 (0.90) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843574 | 0.92 | CHRNA7 (0.84) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843575 | 0.92 | CHRNA7 (0.84) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Fumaric Acid SCHEMBL843892 | 0.89 | CHRNA7 (0.80) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Fumaric Acid SCHEMBL843893 | 0.89 | CHRNA7 (0.80) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL842944 | 0.86 | CHRNA7 (0.76) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843810 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843811 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL842856 | 0.82 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | UNIV CALIFORNIA (US) | 2023-03-30 | — | — | US | claimed |
| US-20220347166-A1 | Schizophrenic Disorder Treatment using Combination Therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2022-11-03 | — | — | US | claimed |
| CN-114845717-A | Treatment of schizophrenia disorders using combination therapy | 剑桥认知有限公司 | 2022-08-02 | — | — | CN | claimed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | claimed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | claimed |
| EP-1587511-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | Pharmacia & Upjohn Company LLC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| EP-1432707-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-30 | — | — | EP | claimed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | claimed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | CHRNA7 1/4885HTR3A 497/4885HTR3E 673/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | CHRNA7 1401/4885HTR3A 2224/4885HTR3E 3192/4885 |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3A 426/4885HTR3E 837/4885 |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | CHRNA3, CHRNA7, CHRNA2 | CHRNA7 2/4885HTR3A 66/4885HTR3E 80/4885 |
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | CHRNA7, CHRNA3, CHRNA6 | CHRNA7 1/4885HTR3A 282/4885HTR3E 262/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CHRNA7 83/4885HTR3A 6/4885HTR3E 15/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | CHRNA7 1/4885HTR3A 32/4885HTR3E 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.